Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
06:10pm, Monday, 04'th Nov 2024
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
04:30pm, Monday, 04'th Nov 2024
Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmake
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
10:31am, Monday, 04'th Nov 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
10:10am, Monday, 04'th Nov 2024
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week
02:00pm, Sunday, 03'rd Nov 2024
U.S. Election Day, a Federal Reserve meeting, and earnings reports from around 100 S&P 500 companies.
Wegovy effective in MASH fatty liver fibrosis trial says Novo
10:26am, Friday, 01'st Nov 2024
Novo Nordisk (NYSE:NVO) has reported another successful trial for its Wegovy or Semaglutide drug, this time in the treatment of fibrosis caused by the fatty liver condition known as MASH. Headline r
Novo's Wegovy helps improve liver fibrosis in late-stage trial
08:36am, Friday, 01'st Nov 2024
Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults wi
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
03:06pm, Wednesday, 30'th Oct 2024
All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo Nor
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
10:36am, Wednesday, 30'th Oct 2024
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website showed on Wednesday.
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
10:14am, Wednesday, 30'th Oct 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported positive results from a preclinical study evaluating the combination of its lead development candidate intranasal foralumab and semaglutide, which
The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
06:56am, Wednesday, 30'th Oct 2024
Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
07:05am, Tuesday, 29'th Oct 2024
One key disease-prevention market is drawing closer to being within reach.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
06:51pm, Monday, 28'th Oct 2024
In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 28'th Oct 2024
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
